I think you have an extra 0 in your number of patients.
How was the target price of $18 derived?
PE = 10x
No. of shares = 901M
At $18, Market cap = $16.2B
With $2B sales, net margin is expected to be 81%? Seems too high, even Sarepta with $1B of revenue is still making a loss...
Perhaps you meant PS of 10x?
Ann: Percheron Therapeutics Limited Corporate Presentation, page-6
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
-0.005(4.76%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.0¢ | $52.56K | 502.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 176914 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 217753 | 2 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |